Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4773894

CC(C)(C)OC(=O)N1CCC(C(=O)N(CCCN2CCC(Cc3ccccc3)CC2)Cc2ccccc2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 5/20 0.55
LMNA P02545 6/20 0.52
GAA P10253 3/20 0.52
KDM4E B2RXH2 2/20 0.52
OPRM1 P35372 2/20 0.49
TP53 P04637 4/20 0.48
MAPT P10636 4/20 0.48
THRB P10828 1/20 0.46
PTPRB P23467 1/20 0.45
PTPN11 Q06124 1/20 0.45
STS P08842 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4777069 0.90 CCR5 (0.68) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4777815 0.86 CCR5 (0.63) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4768574 0.86 CCR5 (0.63) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4777983 0.85 OPRM1 (0.48) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4778140 0.85 CCR5 (0.60) CCR5LMNAGAAKDM4EOPRM1
SCHEMBL4775520 0.85 GAA (0.57) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4775779 0.85 CCR5 (0.64) CCR5LMNAGAAKDM4EOPRM1
SCHEMBL4777052 0.84 CCR5 (0.78) CCR5LMNAOPRM1TP53MAPT
Trifluoroacetic Acid SCHEMBL4775516 0.84 GAA (0.55) CCR5LMNAGAAKDM4EOPRM1
Trifluoroacetic Acid SCHEMBL4773817 0.82 CCR5 (0.60) CCR5LMNAGAAKDM4EOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 CCR5 1/4885LMNA 3240/4885GAA 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.